Please login to the form below

Not currently logged in
Email:
Password:

CTCL

This page shows the latest CTCL news and features for those working in and with pharma, biotech and healthcare.

Seattle Genetics claims key US approval for Adcetris

Seattle Genetics claims key US approval for Adcetris

Last November it was granted FDA approval in adult patients with cutaneous T cell lymphoma (CTCL) and there is more to come.

Latest news

  • Takeda bags EU approval for Adcetris in lymphoma Takeda bags EU approval for Adcetris in lymphoma

    Takeda bags EU approval for Adcetris in lymphoma. Data shows the drug improves PFS and symptom burden in CTCL patients. ... The approval of Adcetris in this setting brings a much needed, effective treatment option to patients living with CTCL, ”she

  • EU nod for Actelion's skin cancer drug Ledaga EU nod for Actelion's skin cancer drug Ledaga

    fungoides-type cutaneous T-cell lymphoma (MF-CTCL) in patients who have received prior skin-directed therapy. ... Mechlorethamine has been used for years as an intravenous treatment for MF-CTCL, and Valchlor also has to compete with unapproved topical

  • Novartis' Farydak gets nod for myeloma in Europe Novartis' Farydak gets nod for myeloma in Europe

    Other HDAC inhibitors such as Merck &Co's first-to-market Zolinza (vorinostat) - which is approved to treat cutaneous T cell lymphoma (CTCL) in 2006 - have also been tested in myeloma

  • Ireland’s Mallinckrodt makes $1.3bn immunotherapy purchase Ireland’s Mallinckrodt makes $1.3bn immunotherapy purchase

    Its lead product Photopheresis is approved by the FDA for palliative treatment of the skin manifestations of cutaneous T-cell lymphoma (CTCL) - a form of blood cancer - in patients who have ... Outside the US, Therakos Photopheresis is also used by

  • BMS signs Opdivo combination pact with Kyowa Hakko Kirin  BMS signs Opdivo combination pact with Kyowa Hakko Kirin 

    Its Japanese licences include: relapsed or refractory CCR4-positive adult T-cell leukaemia-lymphoma (ATL); relapsed or refractory CCR4-positive, peripheral T-cell lymphoma (PTCL); cutaneous T-cell lymphoma (CTCL), and

More from news
Approximately 1 fully matching, plus 12 partially matching documents found.

Latest Intelligence

  • Pharma deals in August 2015 Pharma deals in August 2015

    30600. Therakos. Mallinckrodt. Approved cell therapy platform for the palliative treatment of cutaneous T‐ cell lymphoma [CTCL].

  • Deal Watch table for July 2013 Deal Watch table for July 2013

    387. Ceptaris Therapeutics / Actelion. Acquisition. Valchlor for mycosis fungoides-type CTCL (NDA). ... CTCL = cutaneous T-cell lymphoma. VLP  = virus-like particle produced in plant expression systems .

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hive

We're a healthcare communications agency that does things differently. We put patients at the heart of everything we do, while...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics